血浆蛋白质组学改善癌症患者血栓预测并识别可靶向的IL-17驱动内皮激活
研究对1105种血浆蛋白进行高通量蛋白质组学分析,对象为前瞻性监测VTE的新诊断肺癌或胃癌患者,用贝叶斯概率机器学习构建含11种蛋白标志物和5项临床参数的预测模型,其c统计量为0.84(0.79-0.90),优于Khorana评分0.36(0.27-0.45),并在3期试验外部安慰剂队列中验证;机制上CD200R1降低与D-二聚体升高和血栓风险相关,CD200R1缺陷小鼠呈促血栓状态,抗IL-17A抗体可使其恢复正常。
要点
- 11蛋白+5临床参数的模型预测癌症VTE优于Khorana评分。
- CD200R1降低与D-二聚体升高及血栓风险相关。
- 抗IL-17A抗体在CD200R1缺陷小鼠中恢复正常血栓指标。
核心结论
- 血浆蛋白质组学模型可改善癌症患者VTE预测。
- CD200R1降低与促血栓状态及IL-17A升高相关。
- 抗IL-17A抗体可纠正CD200R1缺陷小鼠的促血栓表型。
研究设计与样本
- 对1105种血浆蛋白进行高通量蛋白质组学分析。
- 对象为新诊断肺癌或胃癌并前瞻性监测VTE的患者。
- 用贝叶斯概率机器学习构建含11种蛋白和5项临床参数的模型。
- 在3期试验外部安慰剂队列中进行正交验证。
- 开展CD200R1缺陷小鼠机制实验及COVID-19研究meta分析。
主要发现
- 模型c统计量0.84(0.79-0.90),Khorana评分为0.36(0.27-0.45)。
- 外部安慰剂队列验证了模型的预测能力。
- CD200R1血浆浓度降低与D-二聚体升高和血栓风险相关。
- CD200R1缺陷小鼠凝血酶-抗凝血酶复合物升高、IL-17A升高和内皮炎症。
- 抗IL-17A抗体使CD200R1缺陷小鼠凝血酶-抗凝血酶复合物正常化。
关键数值与推荐
- 预测模型含11种蛋白标志物和5项临床参数(年龄、性别、VTE史、BMI、血红蛋白)。
- 模型c统计量0.84(0.79-0.90),Khorana评分0.36(0.27-0.45)。
- COVID-19研究meta分析显示使用抗IL-17A抗体者肺血栓栓塞减少。
临床怎么用
- 血浆蛋白质组学模型可用于改善癌症患者VTE风险预测。
- CD200R1和IL-17A通路可作为血栓炎症疾病的潜在治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thrombosis remains a major cause of morbidity and mortality in patients with cancer. Existing risk models fail to reliably predict venous thromboembolism (VTE), underscoring the need for more accurate predictive models. In this study, we conducted a high-throughput proteomic analysis of 1105 plasma proteins in peripheral blood samples from patients with newly diagnosed lung or gastric cancer who were prospectively monitored for VTE development. Using a Bayesian probabilistic machine learning approach, we developed a predictive model incorporating 11 protein biomarkers and five clinical parameters (age, sex, history of VTE, body mass index, and hemoglobin), which outperformed the standardly used Khorana prediction score [c statistic 0.84 (0.79 to 0.90) as compared with 0.36 (0.27 to 0.45)]. Orthogonal validation in an external placebo cohort from a phase 3 trial confirmed the model's predictive power. Further investigation into the mechanistic role of CD200 receptor 1 (CD200R1), an immune checkpoint receptor known to limit leukocyte inflammatory response that contributed strongly to the model, showed that reduced concentrations in plasma correlated with higher D-dimer concentrations and thrombosis risk. CD200R1-deficient mice were characterized by features of a prothrombotic state, with elevated thrombin-antithrombin complexes, increased interleukin-17A (IL-17A), and endothelial inflammation. Administration of anti-IL-17A antibodies to CD200R1-deficient mice normalized thrombin-antithrombin complexes in vivo, and a meta-analysis of human COVID-19 studies showed reduced pulmonary thromboembolism in those on anti-IL-17A antibodies. These findings highlight the utility of plasma proteomics to improve prediction of thrombosis in patients with cancer and to identify unanticipated mechanistic insights and therapeutic targets in thrombo-inflammatory disease.
引用
- Karagkouni D, Brake MA, Patell R, et al. Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation. Sci Transl Med. 2026. PMID: 42308329. doi:10.1126/scitranslmed.adu7160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。